Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)

NEXT STORY
Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
PREV STORY
Insights on the $16.6 Billion Disposable Syringes Global Market to 2026 – Key Drivers and Challenges
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioSig‘s Subsidiary NeuroClear Technologies, Inc. Raises $3.7 million

author_avatar
NASDAQ Market News

NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

 NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE ...

author_avatar
NASDAQ Market News

Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders

SHANGHAI, China and CUPERTINO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group ...

author_avatar
NASDAQ Market News